Posts

Affinity and receptor expression limits tested for LRC-TriCEPS

Dualsystems Biotech AG is testing the limits of the LRC-TriCEPSTM (CaptiRec) technology using antibodies with different affinities against the same target and cells expressing the target receptor with different expression levels.

Limits-of-LRC-TriCEPS

Limits-of-LRC-TriCEPS

Details of the assesment see here

CaptiREC (LRC-TriCEPS) experiment performed at Dualsystems

Dualsystems has performed an example of a CaptiREC (LRC-TriCEPSTM) experiment to identify the target receptor of Anti-EGFR-Antibody on human breast cancer cells (MDA-MB-23):

Positive control ligand (included in the kit): Insulin
Ligand of interest: Anti-human EGF Receptor Antibody
Cells: MDA-MB-231 human breast cancer cells

Detail on the experiment see here

Dualsystems Biotech partners with IBR Inc. to validate the workflow of the CaptiRec Technology

Dualsystems Biotech AG Press Release

Dualsystems Biotech partners with IBR Inc. to validate the workflow of the CaptiRec Technology

Schlieren, Switzerland, January 2014: – Dualsystems Biotech AG has announced it will collaborate with another Swiss laboratory, Institute for Biopharmaceutical Research (IBR Inc.) to validate the CaptiRec Triceps/Ligand Receptor Capture Technology. This technology is used to identify the Cell Membrane Receptors on Living Cells.
The partnership will combine the respective strengths of Dualsystems, a leading service provider for protein interaction at the cell membrane and IBR Inc., a GLP-compliant contract research organization specializing in cell-based assays

Read more